Press Release1 Apr 2024, 08:56 pm
Zydus Lifesciences Receives Approval for New Drug Name 'Usnoflast' from WHO INN
AI Summary
Zydus Lifesciences, a leading discovery-based pharmaceutical company, recently announced the receipt of approval for the name ‘Usnoflast’ as the recommended name for their novel oral small molecule NLRP3 inhibitor, ZYIL1, from the WHO INN. Usnoflast is under clinical development for four indications: Cryopyrin-Associated Periodic Syndromes (CAPS), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, and Ulcerative Colitis.
Key Highlights
- Zydus Lifesciences received approval for the name ‘Usnoflast’ as the recommended name for their NLRP3 inhibitor ZYIL1 from the WHO INN
- Usnoflast is a novel oral small molecule NLRP3 inhibitor under clinical development in 4 indications: CAPS, ALS, Parkinson’s disease, and Ulcerative Colitis
- Studies demonstrate Usnoflast's high potency in human whole blood assays and its ability to suppress inflammation caused by the NLRP3 inflammasome
- Usnoflast has been found to be safe and well-tolerated in Phase I studies
- Zydus established proof-of-concept in Cryopyrin-associated periodic syndromes and published Phase 2 results
- The USFDA has granted Zydus an ‘Orphan Drug Designation’ for Usnoflast